Skip to Content

The effects of anti-CD20 therapy on TFH cells in relapsing-remitting MS

This study presented at ECTRIMS examines the effect of anti-CD20 therapy on T follicular helper (TFH) cells in relapsing-remitting MS. Sahla El Mahdaoui explains how they found a reduction in CD25-negative TFH cells after treatment. These cells are enriched in cerebrospinal fluid in untreated MS patients and linked to disease activity. The findings suggest CD25-negative TFH cells may play a role in MS progression and treatment response.

Sahla El Mahdaoui

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top